Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease ...
Companies aren't slowing down to ask if AI is ready for mental health; they're racing to build it in. Encoding the same ...
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 ...
At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results